Effects of spleen status on early outcomes after hematopoietic cell transplantation

Bone Marrow Transplantation

Volumn 48, Issue 6, 2013, Pages 825-831

  Akpek, G ^a   Pasquini, M C ^b   Logan, B ^b   Agovi, M A ^b   Lazarus, H M ^c   Marks, D I ^d   Bornhaeuser M ^e   Ringden O ^f   Maziarz, R T ^g   Gupta, V ^h   Popat, U ⁱ   Maharaj, D ^j   Bolwell, B J ^k   Rizzo, J D ^b   Ballen, K K ^l   Cooke, K R ^c   McCarthy, P L ^m   Ho, V T ⁿ  

^a UNIVERSITY OF MARYLAND   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j Bethesda Health City   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

^l MASSACHUSETTS GENERAL HOSPITAL   (United States)

^m ROSWELL PARK CANCER INSTITUTE   (United States)

ⁿ DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

engraftment; myeloproliferative disease; SCT; spleen; splenectomy

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; CD34 SELECTION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPHIL ENGRAFTMENT; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLATELET ENGRAFTMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SPLEEN; SPLEEN STATUS; SPLENECTOMY; SPLENOMEGALY; T CELL DEPLETION;

ADOLESCENT; ADULT; ALLOGRAFTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPLEEN; SPLENECTOMY; SURVIVAL RATE; TIME FACTORS;

EID: 84879072722     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.249     Document Type: Article

References (30)

1. Helenglass G, Treleaven J, Parikh P, Aboud H, Smith C, Powles R. Delayed engraftment associated with splenomegaly in patients undergoing bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 1990; 5: 247-251.
2. Battiwalla M, McCarthy PL. Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice. Bone Marrow Transplant 2009; 43: 351-356.
3. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
4. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA et al. American society of clinical oncology growth factors expert panel. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000; 18: 3558-3585.
5. Baughan AS, Worsley AM, McCarthy DM, Hows JM, Catovsky D, Gordon-Smith EC et al. Haematological reconstitution and severity of graft-versus-host disease after bone marrow transplantation for chronic granulocytic leukaemia: the influence of previous splenectomy. Br J Haematol 1984; 56: 445-454.
6. Gluckman E, Devergie A, Bernheim A, Berger R. Splenectomy and bone marrow transplantation in chronic granulocytic leukaemia. Lancet 1983; 1: 1392-1393.
7. Gratwohl A, Goldman J, Gluckman E, Zwaan F. Effect of splenectomy before bonemarrow transplantation on survival in chronic granulocytic leukaemia. Lancet 1985; 2: 1290-1291.
8. Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912-3918.
9. Li Z, Deeg HJ. Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation. Leukemia 2001; 15: 465-467.
10. Li Z, Gooley T, Applebaum FR, Deeg HJ. Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood 2001; 97: 2180-2181.
11. Martino R, Altes A, Muniz-Diaz E, Brunet S, Sureda A, Domingo-Albos A et al. Reduced transfusion requirements in a splenectomized patient undergoing bone marrow transplantation. Acta Haematol 1994; 92: 167-168.
12. Stewart WA, Pearce R, Kirkland KE, Bloor A, Thomson K, Apperley J et al. The role of allogeneic SCT in primary myelofibrosis: a British society for blood and marrow transplantation study. Bone Marrow Transplant 2010; 45: 1587-1593.
13. Ringden O, Nilsson B. Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation 1985; 40: 39-44.
14. Sundin M, Le Blanc K, Ringden O, Barkholt L, Omazic B, Lergin C et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006; 91: 1059-1067.
15. Elliott MA, Tefferi A. Splenic irradiation in myelofibrosis with myeloid metaplasia: a review. Blood Rev 1999; 13: 163-170.
16. Pasquini MC, Wang Z, Horowitz M, Gale RP. 2010 report from the center for international blood and marrow transplant research (CIBMTR): current uses and outcomes of hematopoietic cell transplant for blood and bone marrow disorders. In: Cecka JM, Terazaki PI (eds) Clinical Transplants 2010. The Terasaki Foundation Laboratory: Los Angeles, 2011.
17. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
18. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
19. Jetmore A, Plett PA, Tong X, Wolber FM, Breese R, Abonour R et al. Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34(\+) cells transplanted into conditioned NOD/SCID recipients. Blood 2002; 99: 1585-1593.
20. Szilvassy SJ, Bass MJ, Van Zant G, Grimes B. Organ-selective homing defines engraftment kinetics of murine hematopoietic stem cells and is compromised by ex vivo expansion. Blood 1999; 93: 1557-1566.
21. van Hennik PB, de Koning AE, Ploemacher RE. Seeding efficiency of primitive human hematopoietic cells in nonobese diabetic/severe combined immune deficiency mice: implications for stem cell frequency assessment. Blood 1999; 94: 3055-3061.
22. Wright DE, Wagers AJ, Gulati AP, Johnson FL, Weissman IL. Physiological migration of hematopoietic stem and progenitor cells. Science 2001; 294: 1933-1936.
23. Plett PA, Frankovitz SM, Orschell CM. Distribution of marrow repopulating cells between bone marrow and spleen early after transplantation. Blood 2003; 102: 2285-2291.
24. Smith LH, McKinley Jr TW. Recovery from radiation injury with and without bone marrow transplantation: effects of splenectomy. Radiat Res 1970; 44: 248-261.
25. Tanaka N. Experimental studies on role of spleen in recovery from radiation injury in mice. 3. Effect of splenectomy on survival of mice with spleen and bone marrow transplantation following lethal x-irradiation. Hiroshima J Med Sci 1966; 15: 347-378.
26. Richard C, Romon I, Perez-Encinas M, Baro J, Rabunal MJ, Mazorra F et al. Splenectomy for poor graft function after allogeneic bone marrow transplantation in patients with chronic myeloid leukemia. Leukemia 1996; 10: 1615-1618.
27. Robin M, Esperou H, de Latour RP, Petropoulou AD, Xhaard A, Ribaud P et al. Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis. Br J Haematol 150: 721-724.
28. von Bueltzingsloewen A, Bordigoni P, Dorvaux Y, Witz F, Schmitt C, Chastagner P et al. Splenectomy may reverse pancytopenia occurring after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14: 339-340.
29. Park AE, Birgisson G, Mastrangelo MJ, Marcaccio MJ, Witzke DB. Laparoscopic splenectomy: outcomes and lessons learned from over 200 cases. Surgery 2000; 128: 660-667.
30. Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, Van Lint MT et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 2010; 45: 458-463.